Literature DB >> 20681405

Anticancer effect of a novel 2-arylidene-4,7-dimethyl indan-1-one against human breast adenocarcinoma cell line by G2/M cell cycle arrest.

R Prasanna1, C C Harish.   

Abstract

A novel compound 2-arylidene-4,7-dimethyl indan-1-one synthesized was screened for anticancer effect against the human breast adenocarcinoma cell line, MCF-7. An IC50 value of > or = 80 microM, nontoxic to the normal breast cell line HBL-100, showed complete inhibition of the MCF-7 cells. Analysis of mechanisms showed nuclear fragmentation and DNA laddering in gel electrophoresis. GSH and GR levels were found to be reduced after the compound treatment. Cell cycle analysis using fluorescent cytometry revealed G2/M phase arrest, which indicates the compound deserves consideration for further studies against cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20681405     DOI: 10.3727/096504010x12704916124747

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  3 in total

1.  CB-RAF600E-1 exerts efficacy in vemurafenib-resistant and non-resistant-melanoma cells via dual inhibition of RAS/RAF/MEK/ERK and PI3K/Akt signaling pathways.

Authors:  Mesfer Al Shahrani; Prasanna Rajagopalan; Mohammad Abohassan; Mohammad Alshahrani; Yasser Alraey
Journal:  Saudi J Biol Sci       Date:  2022-04-23       Impact factor: 4.052

2.  The SMAC mimetic AT-101 exhibits anti-tumor and anti-metastasis activity in lung adenocarcinoma cells by the IAPs/ caspase-dependent apoptosis and p65-NFƙB cross-talk.

Authors:  Irfan Ahmad; Safia Irfan; Mirza Masroor Ali Beg; Hossam Kamli; Syed Parveen Ali; Naseem Begum; Mohammad Y Alshahrani; Prasanna Rajagopalan
Journal:  Iran J Basic Med Sci       Date:  2021-07       Impact factor: 2.699

3.  A Combined Chemical, Computational, and In Vitro Approach Identifies SBL-105 as Novel DHODH Inhibitor in Acute Myeloid Leukemia Cells.

Authors:  Hossam Kamli; Gaffar S Zaman; Ahmad Shaikh; Abdullah A Mobarki; Prasanna Rajagopalan
Journal:  Oncol Res       Date:  2021-08-05       Impact factor: 5.574

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.